2.65

5.36% -0.15

After Hours: 2.65

Codexis Inc. (CDXS)

Overview News Price History Option Chain Discussions Forecast

Codexis Inc. stock is currently priced at $2.65, with a 24-hour trading volume of 271.31K. It has seen a -5.36% decreased in the last 24 hours and a -23.19% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.82 pivot point. If it approaches the $2.57 support level, significant changes may occur.

Previous Close:

$2.80

Open:

$2.72

24h Volume:

271.31K

Market Cap:

$186.30M

Revenue:

$70.14M

Net Income/Loss:

$-76.24M

P/E Ratio:

-3.1176

EPS:

-0.85

Net Cash Flow:

$-57.06M

1W Performance:

-5.36%

1M Performance:

-23.19%

6M Performance:

+59.64%

1Y Performance:

-34.89%

1D Range:

$2.64

$2.7399

52W Range:

$1.45

$4.91

Codexis Inc. Stock (CDXS) Company Profile

Name

Codexis Inc.

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

650-421-8100

Address

200 Penobscot Drive, Redwood City, CA

Employee

116

Twitter

@codexisinc

Next Earnings Date

2024-05-02

Latest SEC Filings

CDXS's Discussions on Twitter

Codexis Inc. Stock (CDXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Resumed	Piper Sandler	Overweight
Mar-02-22	Resumed	Cowen	Outperform
Apr-12-21	Initiated	Piper Sandler	Overweight
Mar-01-21	Initiated	Stifel	Buy
Feb-26-21	Reiterated	H.C. Wainwright	Buy
Mar-10-20	Initiated	The Benchmark Company	Buy
Jan-17-19	Upgrade	First Analysis Sec	Neutral → Outperform
May-16-18	Initiated	Stephens	Overweight
Oct-13-17	Reiterated	H.C. Wainwright	Buy
May-31-17	Initiated	Jefferies	Buy
Jan-26-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Jan-04-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-06-16	Initiated	H.C. Wainwright	Buy

View All

Codexis Inc. Stock (CDXS) Latest News

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

GlobeNewswire Inc.

Codexis Inc. Stock (CDXS) Financials Data

Codexis Inc. (CDXS) Revenue 2024

CDXS reported a revenue (TTM) of $70.14 million for the quarter ending December 31, 2023, a -49.39% decline year-over-year.

Codexis Inc. (CDXS) Net Income 2024

CDXS net income (TTM) was -$76.24 million for the quarter ending December 31, 2023, a -126.96% decrease year-over-year.

Codexis Inc. (CDXS) Cash Flow 2024

CDXS recorded a free cash flow (TTM) of -$57.06 million for the quarter ending December 31, 2023, a -2,017% decrease year-over-year.

Codexis Inc. (CDXS) Earnings per Share 2024

CDXS earnings per share (TTM) was -$1.11 for the quarter ending December 31, 2023, a -117.65% decline year-over-year.

Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.